Back to top

Amgen Halts Bemarituzumab Gastric Cancer Trial, Shifting Oncology Expectations

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. has stopped a late stage study testing bemarituzumab in advanced ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Amgen Inc. (AMGN)